Major depression and the metabolic syndrome (MetS) are interacting clinical conditions influenced by genetic susceptibility. For both disorders, impaired serotonergic neurotransmission in specific brain areas has been suggested. This led us to investigate whether variants in the gene coding for tryptophan hydroxylase 2 (TPH2), the brain-specific and rate-limiting enzyme for serotonin biosynthesis, might be predictive for an increased liability for the development of MetS in depressed patients. In a case-control study consisting of 988 patients with recurrent unipolar depression (RUD) and 1023 psychiatric healthy controls, MetS components were ascertained according to the International Diabetes Foundation criteria. A total of 41 single nucleotide polymorphisms fully covering the TPH2 gene region were genotyped in stage 1 (300 patients/300 controls), resulting in significant genetic associations of polymorphisms located in exon 7 and intron 8 of TPH2 and the occurrence of MetS in depressed patients after correction for age, gender and multiple testing (51 RUD-MetS/179 RUD-non-MetS). We were able to confirm the significant association of rs17110690 in stage 2 (688 patients/723 controls; 110 RUD-MetS/549 RUD-non-MetS) and to link risk-genotypes and risk-haplotypes for MetS to lower TPH2 mRNA expression and to lower 5-hydroxyindoleacetic acid levels in cerebrospinal fluid previously reported in functional studies. Our findings suggest that TPH2 polymorphisms characterize a subgroup of depressed patients who are especially prone to develop metabolic disorders induced by a genotype-dependent impairment of serotonergic neurotransmission. Identifying depressed patients at high risk for MetS using genetic variants could have direct clinical impact on individualized disease management and prevention strategies.
Introduction
Metabolic syndrome (MetS) [1] [2] [3] and major depression (MD) 4, 5 are substantial public health problems with increasing prevalence worldwide and both disorders contribute to an increased risk for cardiovascular disease (CVD). [6] [7] [8] Moreover, genetic correlation between MD and CVD suggesting common genetic factors has been reported in a large twin study. 9 The metabolic disorders framing the MetS are defined as dysregulation of glucose metabolism, central obesity, dysregulation of plasma lipids and elevated blood pressure. 6, 7 Epidemiological and clinical studies strongly suggest comorbidity between MD and MetS. [10] [11] [12] On the one hand, MD patients harbor an elevated risk for insulin resistance, 13 obesity 14 and, consequently MetS, 10 on the other hand, patients suffering from MetS are at a higher risk for depressive disorders. 11, 12, 15 Beyond environmental factors such as sedentary lifestyle, 16 genetic susceptibility is important in the development of MetS. 17, 18 Several genetic associations with MetS or its components have been reported with most studies focusing on insulin signaling, glucose homeostasis, lipoprotein metabolism pathways and genes involved in adipogenesis, inflammation processes, vascular function and coagulation. 19, 20 Likewise, MD has a high heritability. 21, 22 Genetic association studies in MD in this context were mainly targeting serotonergic and noradrenergic neurotransmitter systems, hypothalamic-pituitary-adrenocortical (HPA) axis and neurotrophic systems, but have not been able to identify substantial and reproducible genetic risk factors so far. 23, 24 Several biological systems have been shown to contribute to this interrelationship between MD and metabolic disorders as well as appetite and weight regulation. In this context, disturbances in brain serotonin system have been suggested to be important in the pathophysiology of both MD and metabolic disorders. [25] [26] [27] Lower serotonergic activity in the central nervous system (CNS) has been associated with both metabolic disorders 26, 28 and MD. 29, 30 Furthermore, selective serotonin reuptake inhibitors (SSRIs) have been shown to be successful for the treatment of MD, 31 metabolic disorders 32, 33 and presumably for the prevention of cardiovascular morbidity and mortality, 34 emphasizing the importance of the serotonergic system in the pathophysiology of MetS and MD.
The recently identified brain-specific isoform of tryptophan hydroxylase, tryptophan hydroxylase 2 (TPH2), which is the rate-limiting enzyme for brain serotonin biosynthesis, is a strong candidate for the pathophysiology of both MetS and MD. 35 TPH2, preferentially expressed in specific brain regions, 36, 37 consists of 490 amino acids and is encoded on chromosome 12q21.1 with a length of 93.6 kbp, composed of 11 exons and 10 introns. In particular, affective disorder spectrum diseases, such as bipolar disorder, recurrent unipolar depression (RUD) as well as suicide and suicide attempts, have been linked to TPH2 in genetic association studies. [38] [39] [40] [41] [42] [43] [44] [45] To the best of our knowledge, no association study of TPH2 and metabolic disorders has yet been reported.
As comorbid metabolic disorders in depressed patients represent a major public health issue and additionally may impact the treatment of MD, 46 identifying depressed patients at high risk for MetS is of great importance for the treatment and clinical management of depressive patients. As the central serotonergic system is likely to have an important function in both MD and metabolic disorders, we investigated whether genetic variants in the TPH2 gene are associated with RUD or MetS or may contribute to the elevated risk for MetS occurring in RUD patients participating in a large case-control study.
Materials and methods

Sample description
A total of 988 patients (323 men and 665 women) with RUD were recruited from in-and outpatients of the Max Planck Institute of Psychiatry (MPI) in Munich, Germany, and psychiatric hospitals. 47 Patients were diagnosed by WHO-certified raters according to Diagnostic and Statistical Manual of Mental Disorders, fourth edn, using a computer-assisted version of the Schedules for Clinical Assessment in Neuropsychiatry. 48 Only Caucasians older than 18 years with at least two moderate or severe depressive episodes were included. Exclusion criteria were the presence of manic or hypomanic episodes, mood incongruent psychotic symptoms, the presence of a lifetime diagnosis of drug abuse and depressive symptoms only secondary to alcohol or substance abuse or dependence or to a medical illness or medication. Ethnicity was recorded using a self-report questionnaire for perceived nationality, first language and ethnicity of subjects themselves, parents and all four grandparents. All included patients were Caucasian and 91.2% of German origin. Mean age was 50.82 ± 13.70 years.
A total of 1023 controls (334 men and 689 women) matched for ethnicity, sex and age (5-year intervals, mean age: 50.80 ± 13.90 years) were recruited at the MPI. Controls were randomly selected from a Munich-based community sample and screened for the presence of anxiety and affective disorders using the Composite International Diagnostic Screener. 49 Only individuals negative for the above-mentioned disorders were included. All controls were Caucasian and 93.04% of German origin.
The study was approved by the Ethics Committee of the Ludwig-Maximilians University, Munich, and written informed consent was obtained from all subjects.
Assessment of MetS components
History of metabolic disorders was recorded from all subjects with a self-report questionnaire asking for diagnoses of type 2 diabetes, high blood lipids, high blood pressure and obesity and for receiving physical or pharmacological treatment for the above-named disorders. A physician was available to assist the subjects in case of any question.
Blood pressure was measured at rest using an automatic sphygmomanometer and waist circumference was measured at the level of the iliac crest. Cholesterol, triglycerides, high-density lipoprotein (HDL) and low-density lipoprotein cholesterol, glucose and glycosylated hemoglobin were analyzed with standard laboratory techniques. For diagnoses of all MetS components, we combined all information from self-report, interview, physical examination and laboratory analyses according to the International Diabetes Foundation (IDF) criteria. 50 Eight subjects (three patients, five controls) with type 1 diabetes were excluded from further analysis.
DNA preparation
On enrollment in the study, 40 ml of EDTA blood was drawn from each subject. DNA was extracted from fresh blood using the Puregene whole blood DNA extraction kit (Gentra Systems Inc., MN, USA).
SNP selection and genotyping
Sequences of 41 single nucleotide polymorphisms (SNPs) throughout the TPH2 gene were selected from Celera (http://www.celera.com) and dbSNP (http://www.ncbi.nlm.nih/) with a mean distance of 2.8 kb (Table 1) . We aimed to ensure a 100% marker coverage of the Human Reference sequence (RefSeq) 51 of the TPH2 gene, including the whole TPH2 promoter region determined by Genomatix [38] [39] [40] [41] [42] [43] [44] [45] with positive associations with affective disorders and all five known coding SNPs (dbSNP) were added to the SNP panel. And, we have randomly chosen six SNPs without known genotype distributions, whenever the intermarker distance between two SNPs was bigger than 5.5 kb.
We applied a split-sample design, 41 SNPs were genotyped in stage 1 (300 RUD patients/300 controls). Significant associations after correction for multiple testing were investigated in stage 2 (688 RUD patients/723 controls).
Genotyping was completed on a matrix-assisted laser desorption/ionization time-of-flight mass spectrometer (MassARRAY system), using the Spectro-DESIGNER software (Sequenom, CA, USA) for primer selection, multiplexing and the homogeneous mass extension process for producing primer extension products. 52 All primer sequences are available on request. For examination of LD pattern, we used D 0 and r 2 measures. 53 Visualization of LD measures and haplotype analysis was performed using version 4.1 of HAPLOVIEW. 54 LD blocks were defined according to the confidence interval method by Gabriel et al. 55 
Statistical analysis
MetS and metabolic disorders in patients and controls
We compared the prevalence of MetS and all MetS components in patients and controls using odds ratio (OR) and calculating 95% confidence intervals after logarithmic transformation. For comparing the number of metabolic diseases in patients and controls, we used a general linear model with age and gender as covariates. These analyses were performed with SPSS version 15.0.
Testing for deviation from the Hardy-Weinberg equilibrium SNPs were tested for genotyping/population consistency using the exact test of Hardy-Weinberg equilibrium (HWE) as described by Wigginton et al. 57 MAFs were calculated. Polymorphisms with a corrected HWE P-value lower than 0.05 and a MAF lower than 0.025 were excluded (Table 1) .
Genetic association analysis and correction for multiple testing Statistical analysis for case-control association was performed in the explorative part (stage 1; 300 patients/300 controls) for genetic associations with RUD and the prevalence of MetS in depressed patients, controls and all subjects using Fisher's exact test. We performed analyses of five different genetic models (genotypic, allelic, dominant-recessive, recessive-dominant, heterozygous advantage/disadvantage) and calculated OR with 95% confidence intervals using 2 Â 2 and 2 Â 3 contingency tables, respectively. Comparison of different genetic models was performed on the basis of the method proposed by Chiano and Clayton. 58 To correct for multiple testing the Westfall-Young permutation method was applied to take advantage of the dependence structure between SNPs and genetic models. 59 We performed the whole analysis scan 100 000 times with phenotypes randomly redistributed over the genotypes. All statistical analyses for genetic associations were performed with WG-Permer, a C þ þ based statistical software program (www.wg-permer.org). In stage 2, the confirmatory part of the study, we genotyped SNPs showing significant association after correction for multiple testing in the exploration sample as described above. Statistical methods for analysis and correction for multiple testing in stage 2 were identical to those described for stage 1.
Disease-genotype interaction
Tests for RUD-genotype interaction for the prevalence of MetS were performed with logistic regression analysis for genotypic and dominant-recessive genetic models. MetS was used as independent variable, rs17110690 genotype, RUD status and the interaction term of rs17110690 genotype Â RUD status were selected as covariates. Logistic regression was performed with SPSS version 15.0.
Results
Genotyping and quality control
Genotyping was successful in 40 of 41 polymorphisms. HWE P-values and MAF are displayed in Table 1 . Two polymorphisms turned out to be monomorphic in our experiment and five polymorphisms were excluded due to deviation from HWE low MAF or assay problems resulting in low call rates ( < 95%).
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MetS and metabolic disorders in RUD patients and controls
The rate of all metabolic disorders constituting the MetS was significantly higher in RUD and, therefore, MetS was significantly more frequent in patients compared to controls. These differences between patients and controls were more distinct in female subjects (Table 2) . RUD patients with and without MetS did not differ significantly in disease duration and number of previous depressive episodes.
Association of genetic variants in TPH2 and RUD
We found nominally significant case-control associations of polymorphisms in TPH2 with the susceptibility for RUD in our exploration sample (Table 3) . These results did not remain significant after correction for multiple testing for all polymorphisms and genetic models. Table 4 ). We had a statistical power of about 61% to detect these associations (calculated for rs17110690).
Association of genetic variants in TPH2 and MetS
In controls (MetS controls: n = 19; non-MetS controls: n = 241) and the combined sample (MetS subjects: n = 70, non-MetS subjects: n = 420), polymorphisms in TPH2 showed no significant association for MetS risk after correction for multiple testing.
To replicate these findings, we genotyped rs11179002 and rs17110690 in the remaining subjects (stage 2) as described above, consisting of 688 patients and 723 controls. In this confirmatory sample, we could successfully replicate the association of rs17110690 with MetS risk in patients with RUD (RUD-MetS patients: n = 110, RUD-non-MetS patients: n = 549; P = 0.02). This association in depressed patients remained significant after correction for multiple testing for both polymorphisms. Genotype distribution was comparable in both samples with the GG genotype of rs17110690 being more prevalent among RUD patients suffering from MetS compared to RUD patients without MetS (Table 5 ). The genotype distribution underlying this association is in concordance with a recessive mode of inheritance. In controls, rs17110690 genotypes were equally distributed in subjects with and without MetS ( Table 5) . No association between rs11179002 and MetS in RUD patients could be detected in stage 2.
As homozygous carriers of the rs17110690 G allele showed the highest rate of MetS in RUD but not in controls, we performed a logistic regression to test for disease-gene interaction between RUD and genotype with respect to MetS. Tests were conducted in the .f. 1, P = 0.007). Including the interaction term rs17110690 Â RUD in the logistic regression analysis resulted in a significant prediction of MetS in both the genotypic and the recessive-dominant model (genotypic model: Wald score 9.61, d.f. 2, P = 0.008; recessive-dominant model (GG): Wald score 9.18, d.f. 1, P = 0.002), whereas rs17110690 alone did not reach significance in this model. The effect of RUD patient status remained significant (P < 0.001). The rate of MetS in patients and controls with respect to the rs17110690 genotype is shown in Figure 1 , illustrating the interaction effect of RUD and genotype with respect to an elevated risk for MetS, which is most pronounced in patients with a history of RUD, who are homozygous for the G allele of rs17110690 in the TPH2 gene.
LD structure of TPH2
Our LD analysis revealed in six LD blocks (Figure 2 ). Block 1 contains the promoter region, 5 0 end and transcription start site of TPH2. The associated SNP, rs17110690, is located in intron 8, LD block 4. The LD structure and allele frequencies in our study are congruent with LD data structure in the CEU sample of the HAPMAP Project (www.hapmap.org). In search of putative functional variants linked to the associated marker, we analyzed the HAPMAP Project data Five of these polymorphisms (rs17110489, rs1487278, rs17110532, rs10506646 and rs12229394) are located near or within phylogenetically conserved genetic regions.
Transcription factor binding sites changed by associated SNP
In silico analysis of transcription factor binding sites (TFBS) applying the Genomatix software and Genome Browser showed that a G to A change of rs17110690 creates a new TFBS for the transcription factors HNF1, BRNF and HOXF. BRNF, a POU 3 domain containing protein (NM_005604) is expressed predominantly in the CNS playing a putative role in neuronal development, HNF1 is the hepatic nuclear factor 1 (NM_000545) and HOXF (NM_003658) encodes a member of the homeobox transcription factor family.
Functional polymorphisms in TPH2 linked to the associated SNP rs17110690
Several studies report functional changes in gene expression and differences in 5-hydroxyindoleacetic acid (5-HIAA) levels for genetic variants and haplotypes, which are in LD to our associated marker rs17110690. 42, 60, 61 Lim et al. 61 analyzed TPH2 mRNA expression in median and dorsal raphe nuclei of human pons sections and detected an elevated TPH2 mRNA expression in subjects carrying haplotypes containing rs7305115 allele A. The SNP rs7305115 is in LD (r 2 = 0.4, D 0 = 1.0) with our associated marker, and allele A of rs7305115 cosegregates with allele A of rs17110690 in our study (Figure 2) . Accordingly, Zhou et al. 42 showed lower concentrations of the serotonin metabolite 5-HIAA in human cerebrospinal fluid (CSF) levels in subjects with haplotypes containing the G allele of rs7305115 (Figure 2) . Furthermore, two SNPs in intron 8 (rs1352251 and rs1473473) nearby our marker rs17110690 were used for haplotype building by the authors. In rhesus monkeys, Chen et al. 60 demonstrated that SNPs and haplotypes located around rs17110690 in the 3 0 region of the TPH2 gene influence gene expression.
Therefore, the genotype GG of rs17110690 can be linked to genetic variants associated with lower TPH2 mRNA expression and lower CNS serotonin levels.
Genotyping and analysis of rs7305115
Previous studies suggested an association between rs7305115 and the genetic region comprising this polymorphism with alterations in gene expression and levels of serotonin metabolites. As rs7305115 is in LD with rs17110690, we additionally genotyped rs7305115 in the complete sample. Genotyping and quality control was performed as described above. Association analysis revealed a significant result for rs7305115 and the risk for MetS only in RUD patients ( Table 5 ). The allelic model turned out to be the bestfitting genetic model for this association. The recessive model for the GG genotype of rs7305115 displayed a trend with approaching significance (P < 0.1) corresponding to the significant finding observed for rs17110690. The interaction of rs7305115 Â patient status on the risk for MetS showed a significant result in both the genotypic and the recessive-dominant model (genotypic model: Wald score 7.28, d.f. 2, P = 0.026; dominant-recessive model (GG): Wald score 18.10, d.f. 1, P = 0.00002) consistent with the results for rs17110690.
Haplotype analysis
Haplotype analysis in RUD patients combining rs7305115 and rs17110690 revealed three haplotypes: GG, frequency (f) = 0.59; AA, f = 0.22 and AG, f = 0.18. Haplotype association testing resulted in a significant association of GG haplotype with MetS in RUD patients (w 2 = 4.17, P = 0.041); AA haplotype was inversely associated with MetS as protective haplotype in RUD patients (w 2 = 11.22, P = 0.001). Haplotype analysis in controls using the same SNPs showed a similar haplotype frequency distribution (GG, f = 0.60; AA, f = 0.20 and AG, f = 0.19), whereas no significant result was obtained for MetS.
Discussion
Our study revealed a genetic association of SNPs in the TPH2 gene with the prevalence of MetS in RUD patients. This association emerged as a gene-disease interaction with the highest risk for MetS in RUD patients carrying the G allele of rs17110690 and rs7305115. To the best of our knowledge, our study is the first to identify a genetic modifier of depressionassociated MetS.
Besides influencing a broad spectrum of behavioral functions disturbed in affective disorders including control of mood, sleep-wake cycle, sexual behavior and cognition, the serotonergic neurotransmitter system also influences appetite and weight regula- 
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S Kloiber et al tion. 29, 62 Decreased concentrations of the serotonin metabolite 5-HIAA in CSF and brain tissues of depressed individuals and suicide victims/attempters also point toward a decrease of serotonergic neurotransmission in affective disorders. 29, 30, 63 Furthermore, the serotonergic system has been shown to be involved in appetite and weight regulation and to modify the risk for metabolic disorders, as previous studies reported reduced CSF serotonin levels and decreased CNS serotonergic responsivity in MetS and obesity. 26, 28 On the other hand, treatment with SSRIs decreases appetite and induces weight loss, 25, 64 suggesting that dysregulation in central serotonergic system is important in obesity and MetS.
Previous genetic studies demonstrated polymorphism-related changes in gene function, gene expression and regulation of TPH2. 38, 42, 44, 60, 61 Several of these studies also reported changes in gene expression and differences in 5-HIAA levels related to the associated TPH2 polymorphisms in our study. Particularly, for rs7305115, which is in LD with the marker rs17110690, functional alterations in cerebral mRNA expression of TPH2 as well as altered CSF 5-HIAA levels have been reported. 42, 60, 61 Both polymorphisms, rs7305115 and rs17110690, and the G-G haplotype of both were significantly associated with an elevated risk for MetS in RUD patients in our study. Combining the functional data with our findings, the G allele of both rs7305115 and rs17110690, associated with elevated occurrence of MetS in RUD patients, can be linked to lower cerebral TPH2 mRNA expression and lower CNS serotonin levels.
In consideration of all these studies, our findings of functional genetic polymorphisms in TPH2 associated with MetS in RUD point toward an impairment of serotonergic neurotransmission as mediator for increased risk for metabolic disorders among patients with MD. Furthermore, direct effects of the serotonergic system or an interaction with the HPA axis 64, 65 could explain the interrelationship of MetS and MD. In fact, several studies indicate an interaction of glucocorticoids and TPH2 or its functional genetic variants, respectively. 60, 66, 67 In healthy individuals without a history of depression, we were unable to detect an effect of TPH2 polymorphisms on the occurrence of MetS. This difference among patients and controls could be explained by the interaction of genetic polymorphisms in TPH2 and RUD aggravating the monoamine deficit, which leads to metabolic disorders. The decrease in serotonergic neurotransmission in combination with certain TPH2 polymorphisms further decreasing serotonergic activity may in combination increase the risk for MetS in depressed patients.
In concordance with prior clinical and epidemiological observations, 10, 68 we found a significantly higher prevalence of the MetS in both male and female patients with RUD compared to controls with the most pronounced (approximately threefold increase) MetS risk in female RUD patients. 10, 12, 69 As the association between TPH2 polymorphisms and RUD did not withstand correction for multiple testing, we were unable to replicate previous positive reports about TPH2 effects on affective disorders.
Despite the sample size of 161 RUD patients with MetS in the combined sample, the sufficient power to detect this interaction as well as the replication in both subsamples make a false positive association less likely. As we used a split-sample design in our association study, these findings need to be replicated in an independent RUD sample. Several psychopharmacological substances have been described to induce weight gain in psychiatric patients 70 and could possibly interact with the detected genetic effect. As entire pretreatment information could not be obtained for most patients, we cannot exclude influences of previous psychopharmacological therapy on the development of MetS in the patients of our study. However, as disease duration and number of previous depressive episodes displayed no influence on MetS prevalence in patients, a gene-disease interaction of TPH2 polymorphisms and diagnosis of RUD seems a likely explanation of our findings.
Taken together, our findings suggest that functional genetic variants in TPH2 previously linked to decreased serotonergic activity are also associated with the prevalence of MetS in individuals with a history of RUD displayed by an interaction effect between depression and TPH2 genotype with respect to MetS. We suggest that genetic variants in TPH2 are involved in the susceptibility for metabolic disturbances and the development of metabolic disorders and MetS in recurrent depression and therefore characterize a subgroup of depressed patients, who are especially prone to develop metabolic disorders, MetS and subsequent disorders such as CVD.
Identifying depressed patients at high risk for MetS using genetic variants could possibly have direct clinical impact on individualized disease management, 71 such as the commencement of prevention strategies, and specific treatments at an early stage of the disorder.
